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Comparative genomics and 
genotype-phenotype associations 
in Bifidobacterium breve
Francesca Bottacini1, Ruth Morrissey1, Maria Esteban-Torres1, Kieran James1,2, Justin van Breen1, 
Evgenia Dikareva1, Muireann Egan1, Jolanda Lambert3, Kees van Limpt3, Jan Knol  3,4, 
Mary O’Connell Motherway1 & Douwe van Sinderen1,2
Bifidobacteria are common members of the gastro-intestinal microbiota of a broad range of animal 
hosts. Their successful adaptation to this particular niche is linked to their saccharolytic metabolism, 
which is supported by a wide range of glycosyl hydrolases. In the current study a large-scale gene-
trait matching (GTM) effort was performed to explore glycan degradation capabilities in B. breve. By 
correlating the presence/absence of genes and associated genomic clusters with growth/no-growth 
patterns across a dataset of 20 Bifidobacterium breve strains and nearly 80 different potential growth 
substrates, we not only validated the approach for a number of previously characterized carbohydrate 
utilization clusters, but we were also able to discover novel genetic clusters linked to the metabolism of 
salicin and sucrose. Using GTM, genetic associations were also established for antibiotic resistance and 
exopolysaccharide production, thereby identifying (novel) bifidobacterial antibiotic resistance markers 
and showing that the GTM approach is applicable to a variety of phenotypes. Overall, the GTM findings 
clearly expand our knowledge on members of the B. breve species, in particular how their variable 
genetic features can be linked to specific phenotypes.
Bifidobacteria are commonly encountered, Gram-positive, rod-shaped, anaerobic and saccharolytic commensals 
of the gastrointestinal tract of mammals, including humans, where their presence is believed to contribute to the 
maintenance of a healthy gut1,2. The positive effects that have been attributed to bifidobacteria include reinforce-
ment of the host intestinal barrier, competitive exclusion of pathogens, modulation of the immune response, 
(micro)nutrient supplementation, and enhancement/expansion of host metabolism3–5. It has been shown that the 
microbiota of healthy newborns is highly populated by ‘infant type’ bifidobacteria, such as Bifidobacterium breve, 
Bifidobacterium longum spp. longum/infantis and Bifidobacterium bifidum6,7. In this context, members of these 
species are believed to play a crucial role in the healthy development of the infant gut8–10.
Bifidobacteria rely on diet- and/or host-derived glycans (such as human milk oligosaccharides in the case 
of ‘infant type’ bifidobacteria) to support their metabolic activities and persistence in the gut11–13. For this rea-
son the Bifidobacterium pan-genome consists of a relatively high percentage (~13.5%) genes assigned to glycan 
metabolism14 and their glycan-degrading capabilities can be further expanded through resource-sharing and 
cross-feeding strategies involving other members of the gut community15–17.
B. breve, a common bifidobacterial member of the infant microbiota6,18,19, represents one of the most exten-
sively studied and characterized bifidobacterial species from a comparative and functional genomics perspective. 
A prototypical strain of this species, B. breve UCC2003, has been the subject of a considerable number of func-
tional studies, revealing this strain’s ability to utilize host-derived glycans (e.g. various human milk oligosac-
charides, and mucin-derived sulphated sugars, fucose and sialic acid)16,20,21, as well as a range of dietary, mostly 
plant-derived, mono-, oligo- and polysaccharides (such as glucose, fructose, ribose, sucrose, lactose, melezitose, 
raffinose, cellodextrin, galactan and starch)21–28.
Based on a comparative and pan-genome analysis conducted on thirteen representatives of the B. breve spe-
cies, variable genetic features (the variome) were identified that are responsible for strain diversification, includ-
ing genes involved in host or environment interactions, such as biosynthesis of cell surface-exposed structures 
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and exopolysaccharide (EPS), and in defense mechanisms active against invading foreign DNA (i.e. CRISPR/Cas 
systems and R/M systems)22. In addition, these B. breve representatives exhibit a diverse range of glycan hydrolytic 
activities, which are typically encoded by carbohydrate-specific utilization clusters that commonly also contain 
genes specifying a transcriptional regulator and components of ABC transport systems29.
A combination of in silico comparative analysis and experimental data on growth on a number of different 
carbon sources has shown that a so-called gene-trait matching (GTM) approach can be employed to elucidate 
genes responsible for carbohydrate metabolism by B. breve22. The current study represents a substantial expansion 
of our previous phenotypic investigation of this species. By applying GTM to a dataset of 20 B. breve genomes 
tested for their growth performance on 77 different saccharidic substrates, we identified two previously unchar-
acterized carbohydrate utilization gene clusters. Furthermore, extension of our approach to EPS production and 
antibiotic resistance resulted in novel findings which significantly expands our knowledge on members of this 
bifidobacterial species.
Results and Discussion
Comparative genomics of 20 B. breve strains and relative pan-genome. In the present study a 
comparative genome analysis of 20 genetically distinct strains of B. breve was carried out to serve as a basis for a 
comprehensive GTM analysis, aimed at linking genetic features with strain-specific phenotypic properties. The 
genome sequences of the selected isolates had previously been obtained as part of a comparative methylome anal-
ysis of B. breve aimed at increasing the genetic accessibility of member of this species30. From this strain collection 
we selected a subset of 20 non-clonal B. breve representatives (Supplemental Table S1), for each of which Pacbio 
genome sequencing and subsequent assembly resulted in a single genome contig with over 100-fold sequence 
coverage. These strains were subjected to a comprehensive phenotypic assessment, which also included strain 
B. breve UCC2003 as a prototype for this species31.
In order to provide an updated and comprehensive estimation of the B. breve pan-genome and to deter-
mine which fraction of the total gene content assigned to this species is represented by the 20 assessed strains, 
a pan-genome analysis was performed among 73 B. breve representatives available in public databases inclusive 
of the 20 strains which were selected for GTM analysis within this study (Supplemental Table S2). Strains were 
selected for pan-genome analysis based on the degree of completeness of their genome sequence (total number 
of bases > 2 Mbp). Comparing our current analysis with a previous report22, we observed that the core-genome 
previously computed for 13 B. breve representatives (1307 gene families) is only slightly larger in size than the 
one obtained from 73 representatives (1282 gene families). This indicates that the analysis conducted on 13 repre-
sentatives already provided a comprehensive overview of the core structure of the genome of this species. In con-
trast, the size of the calculated pan-genome nearly doubled (total number of 6138 gene families vs the previously 
computed 3667) (Fig. 1). In the present study the inclusion of 73 representatives in the pan-genome calculation 
(curve determined as least squares fit of the power law n = k Nγ)32 resulted in an exponent γ = 0.29 consistent with 
an open pan genome (0 < γ < 1), although it appears to be approaching saturation (γ = 0). A closer inspection 
of the dataset revealed that 69% of the variome in B. breve consists of Truly Unique Genes (TUGs), which rep-
resent > 99.9% of the new genes discovered in the pan-genome after the 37th iteration. The predicted functions 
of these TUGs indicate that at least 50% of these genes encode hypothetical, uncharacterized proteins, or genes 
associated with mobile genetic elements. An analysis of the relative G + C mol% revealed that 47% of the iden-
tified TUGs possess a G + C content that deviates from the average (59% ± 4%), suggesting that horizontal gene 
transfer is an important contributor to the acquisition of new genes within the species. It is worth mentioning that 
horizontal DNA transfer by conjugation has previously been described in bifidobacteria33,34. This also suggests 
that such DNA transfer is a factor which will continue to impact on pan-genome determinations of B. breve, par-
ticularly if other bifidobacterial groups involved in this genetic exchange share the same environment.
Comparative analysis of the 20 B. breve strains selected for GTM analysis showed that 1303 gene families 
occur in all examined strains (thus constituting the core-genome of this group), while the remaining 1614 gene 
families are present in some, but not all, members (thus representing the dispensable genome of these 20 strains). 
Of the 1614 gene families that make up the dispensable genome, 385 occur in just one representative (constituting 
the TUGs of this B. breve group) (Fig. 1). Therefore, based on our knowledge of this species to date, the dataset 
of 20 B. breve strains selected for the determination of GTM associations represents approximately 33% of the 
known dispensable genome of B. breve (Fig. 1).
The B. breve glycobiome and associated growth profiles. The in silico prediction of the glycosyl 
hydrolase (GH) content encoded by the 20 B. breve genomes, designated here as the B. breve glycobiome, iden-
tified 95 orthologous genes organized in 29 GH families. Based on our BLASTP and Cazy-mediated GH pro-
filing efforts (see methods section), B. breve appears to possess a consistent number of enzymes active towards 
α-glucosidic linkages (18 orthologues belonging to families GH13 and GH31) usually present in di-, oligo-and 
poly-saccharides (e.g. maltose, starch and related α-glucans) (Fig. 2A). Of note, the GH13 family is represented 
by various paralogs within a given B. breve genome35,36. The apparent importance of B. breve’s ability to hydrolyse 
α-glucosidic linkages is supported by the finding that among the 23 GH-encoding gene families being present 
in all 20 analysed strains (B. breve core-glycobiome; Fig. 2A) eight belong to GH13. Considering that B. breve is 
particularly abundant in early life where starch-containing foods are among the first digestible dietary carbohy-
drates introduced at weaning37, the observed abundance of GH13 in this species may reflect the importance of 
hydrolysing α-glucosidic linkages for their colonization and persistence in the (infant) gut.
The second most frequently identified group of carbohydrate-active enzymes in B. breve is represented by the 
β-glucosidases (belonging to the GH1 and GH3 families, 15 orthologs), which are involved in processing a variety 
of glycan substrates. One particular β-glucosidase in B. breve has been shown to degrade cellobiose and cellodex-
trin38. In addition, bifidobacterial β-glucosidases may be involved in targeting biologically active molecules such 
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as natural phenols or flavonoids, being of particular relevance to the food and pharmaceutical industry38. For this 
reason and with the aim of finding possible substrates to a relatively high and uncharacterized β-glucosidases in 
our dataset (15 families), available plant-derived β-glucans and natural phenols (e.g. cellulose, pectin, salicin, 
esculin, arbutin, raftelin and amygdalin) were incorporated as substrates to be tested in our study (see below).
The third most abundant group of carbohydrate-active enzymes in B. breve is represented by β-galactosidases, 
which typically are members of the GH2 and GH42 families, allowing B. breve to grow on lactose, but also 
galactan and galacto-oligosaccharides (the former also requiring the action of an extracellular, GH53-family 
galactanase), and harvest galactose moieties from mucin- and milk-derived oligosaccharides21,25,29,39,40.
Taken together, the B. breve glycobiome clearly connects predicted saccharolytic activities with dietary substrates 
available in the infant gut. In fact, most of the carbohydrates present in the infant diet, up to weaning, are derived from 
milk and milk-derived products, which are substrates for bifidobacterial β-galactosidases. During the transition from 
a milk-based diet to solid foods (~6 months), fruits and cereals or vegetables are the first foods given to most infants37. 
Furthermore, starch, present in mashed potato, pasta or rice, may constitute an abundant substrate for bifidobacterial 
growth in the large intestine, if it escapes hydrolysis and consequent absorption in the small intestine. This is also con-
sistent with our data showing the presence of a broad set of genes encoding GH13 members (Fig. 2A).
In order to explore substrate utilization by B. breve strains and linking such information with the pres-
ence of genes with a predicted function in carbohydrate metabolism, we determined growth profiles of the 
20 B. breve strains on 77 different carbohydrate-containing compounds (Supplemental Table S3; Fig. 2B). The 
resulting growth profiles revealed that all strains grow well on seven carbohydrates (i.e. lactose, lactulose, malt-
ose, melibiose, raffinose, glucose and GOS) (Fig. 2B). Of the remaining 70 tested carbohydrates, no growth 
was observed in 35 cases (45% of the total), which included various dietary/host-derived carbohydrates (e.g. 
xylose, XOS, glucuronic acid, galacturonic acid, glucans, arabinose, mannose, tagatose, fucose, 2-fucosyllactose 
and mucin), nucleosides (e.g. uridine, thymidine, adenosine, deoxycytidine), but also potential growth sub-
strates for which no information had previously been collected for B. breve and bifidobacteria in general (e.g. 
saponin, cyclomaltoheptaose, γ-cyclodextrin, methyl-D-galactopyranoside, methyl-D-glucopyranoside, 
D-mandelonitrile-β-gentiobioside, methyl-D-glucopyranoside and myo-inositol) (Fig. 2B).
Figure 1. Comparative genomics of 20 Bifidobacterium breve strains. Representation of comparative genomics 
and pan-genome analysis conducted on 20 B. breve strains and additionally compared to 53 publicly available 
B. breve representatives. Panel A: Heatmap representing two-way hierarchical clustering analysis (HCL) 
conducted on the 20 B. breve genomes. Estimation of core-genome and dispensable-genome is also indicated in 
gene families (GF). Panel B: Circular plot representing the distribution of MCL families among B. breve strains 
relative to their position along the chromosome. Absence of families are indicated by white regions, while 
elements of core-genome and dispensable-genome are also highlighted. Panel C: Pan-genome analysis of 73  
B. breve representatives, consisting of the 20 strains used in this study as well as 53 additional, publicly available 
genomes. Pan-genome and core-genome sizes are indicated, as well as the previously estimated pan-genome 
size (Bottacini et al., 2014) for comparative purposes.
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GTM applied to carbon source utilization. The combination of in silico predicted GH content and 
obtained B. breve growth profiles was used to establish associations between a range of substrates and possible 
gene(s) or cluster(s) responsible for their utilization, using a gene-trait matching (GTM) approach. GTM asso-
ciations were established between 332 unique combinations or clusters of occurrence representing presence/
absence of 785 gene families, and growth/no growth phenotype obtained for the 20 B. breve strains analysed. In 
this manner, we identified 23 gene families that exhibited a 100% match between their presence/absence and the 
ability/inability to grow on a particular carbohydrate (i.e. for cellobiose, galactan, mannitol, sorbitol, melezitose, 
ribose and salicin), in addition to a single gene family that exhibits a 95% correlation between its presence and the 
ability to grow on sucrose (Table 1, Fig. 3A).
These GTM results therefore confirm and extend a previous analysis on a much smaller number of strains 
and carbohydrates22, while it furthermore validates the GTM approach in identifying the genetic require-
ments for growth on certain carbohydrates22,23,25–27. More specifically, GTM identified associations between 
carbohydrate-mediated growth and gene clusters known to be involved in the utilization of cellobiose, galactan, 
mannitol, sorbitol, melezitose, ribose, salicin and sucrose (Supplemental Fig. S1).
It is worth noting that involvement of particular genetic clusters in the utilization of certain substrates had 
previously been demonstrated in B. breve UCC2003 using classical techniques (Table 1). An exception to this is 
the sorbitol/mannitol utilization cluster, which was identified by GTM employing a smaller number of B. breve 
strains22. Overall, the GTM method adopted here not only allowed us to corroborate our previous findings, but 
also facilitated the identification of genes involved in sucrose and salicin metabolism.
B. breve NRBB52 is the only strain (of the 20 analysed) that is able to grow on salicin as its sole carbon source. 
This ability is associated with the presence of a gene cluster, which is unique to this strain, and which contains genes 
predicted to encode an esterase (NRBB52_0575), a β-glucosidase (NRBB52_0577), an ABC-type transport system 
(NRBB52_0578-82) and a β-galactosidase (NRBB52_0583) (Supplemental Fig. S1). Esterases and β-glucosidases 
are known to be involved in the enzymatic degradation of salycilates41, and this NRBB52-associated gene cluster 
was indeed shown to be required for utilization of salicin.
In the case of sucrose, 13 out of the 20 analysed B. breve strains were shown to utilize this disaccharide as their 
sole carbon source. GTM association revealed (for 12 out of these 13 strains) two previously uncharacterized genes 
encoding a predicted β-fructosidase or sucrose-6-phosphate hydrolase (Bbr_0020) and a solute binding protein of 
an ABC transporter system (Bbr_0021). It has previously been shown that bifidobacterial β-fructofuranosidases 
constitute enzymes involved in the breakdown of sucrose and sugars with fructose-containing moieties28. In our 
case we also noticed that the absence of this particular cluster in four cases corresponds to lack of growth on 
Figure 2. The B. breve glycobiome and fermentation profiles. Representation of the distribution of glycosyl 
hydrolases (GHs) across B. breve and carbon source utilization. Panel A: Predicted GH-encoding gene content 
of 20 B. breve genomes displayed as a presence/absence heatmap. An additional bar chart indicates the 
abundance of each GH family across the 20 B. breve strains. Panel B: Heatmap representing the fermentation 
profiles of the 20 B. breve strains as based on 77 different substrates.
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Cluster Locus_tags Annotation
GTM 
positive PFAM Reference
Cellobiose Bbr_0104 Ketol-acid reductoisomerase/2-dehydropantoate 2-reductase PF07991 Pokusaeva et al.27
Bbr_0105 Cellodextrin transport system transcriptional regulator PF13377 Pokusaeva et al.27
Bbr_0106 Cellodextrin binding protein X PF13416 Pokusaeva et al.27
Bbr_0107 Cellodextrin transport system permease protein CebF PF00528 Pokusaeva et al.27
Bbr_0108 Cellodextrin transport system permease protein CebG PF00528 Pokusaeva et al.27
Bbr_0109 Beta-glucosidase, cellodextrinase, glycosyl hydrolase X PF00232 Pokusaeva et al.27
Bbr_0110 Ketol-acid reductoisomerase/2-dehydropantoate 2-reductase PF07991 Pokusaeva et al.27
Galactan Bbr_0417 Solute-binding protein of ABC transporter system for sugars PF01547 O’Connell Motherway et al.25
Bbr_0418 Permease protein of ABC transporter system for sugars PF00528 O’Connell Motherway et al.25
Bbr_0419 Permease protein of ABC transporter system for sugars PF00528 O’Connell Motherway et al.25
Bbr_0420 Beta-galactosidase PF02449 O’Connell Motherway et al.25
Bbr_0421 Transcriptional regulator, LacI family PF13377 O’Connell Motherway et al.25
Bbr_0422 Glycosyl hydrolases family 53, Endogalactanase X PF07745 O’Connell Motherway et al.25
Ribose Bbr_1415 Ribokinase PF00294 Pokusaeva et al.26
Bbr_1416 Ribose transport system permease protein rbsD X PF05025 Pokusaeva et al.26
Bbr_1417 D-ribose-binding protein rbsB PF13407 Pokusaeva et al.26
Bbr_1418 Ribose transport system permease protein rbsC PF02653 Pokusaeva et al.26
Bbr_1419 Ribose transport ATP-binding protein rbsA PF00005 Pokusaeva et al.26
Bbr_1420 Transcriptional regulator, LacI family PF13377 Pokusaeva et al.26
Bbr_1421 Conserved hypothetical membrane spanning protein X PF07690 Pokusaeva et al.26
Bbr_1422 pfkB family carbohydrate kinase X PF00294 Pokusaeva et al.26
Bbr_1432 Ribokinase X PF00294 Pokusaeva et al.26
Melezitose Bbr_1855 Alpha-glucosidase PF00128 O’Connell et al.23
Bbr_1856 Alpha-galactosidase X PF05691 O’Connell et al.23
Bbr_1857 Alpha-1,4-glucosidase PF00128 O’Connell et al.23
Bbr_1858 Permease protein of ABC transporter system for sugars PF00528 O’Connell et al.23
Bbr_1859 Permease protein of ABC transporter system for sugars PF00528 O’Connell et al.23
Bbr_1860 Solute binding protein of ABC transporter system for sugars X PF01547 O’Connell et al.23
Mannitol/Sorbitol B7017_1839/NRBB01_1658 Alpha-acetolactate decarboxylase PF03306 Bottacini et al.22
B7017_1840 NRBB01_1659 Hypothetical membrane spanning protein PF14256 Bottacini et al.22
B7017_1841 NRBB01_1660 Aldehyde-alcohol dehydrogenase PF00465 Bottacini et al.22
B7017_1842/ NRBB01_1661 Transcriptional regulator, AraC family PF12833 Bottacini et al.22
B7017_1843/ NRBB01_1662 Alcohol dehydrogenase X PF08240 Bottacini et al.22
B7017_1844/ NRBB01_1663 transporter, major facilitator family protein PF07690 Bottacini et al.22
B7017_1845/ NRBB01_1664 Transcriptional regulator, ROK family PF00480 Bottacini et al.22
B7017_1846/ NRBB01_1665 putative glyoxalase family protein PF12681 Bottacini et al.22
B7017_1847/ NRBB01_1666 ribitol transporter PF07690 Bottacini et al.22
B7017_1848/ NRBB01_1667 Alcohol dehydrogenase X PF08240 Bottacini et al.22
Salicin NRBB52_0572 Alcohol dehydrogenase PF08240 Uncharacterized
NRBB52_0573 Hypothetical protein PF13173 Uncharacterized
NRBB52_0574 Hypothetical protein PF02518 Uncharacterized
NRBB52_0575 Carbohydrate esterase X PF03629 Uncharacterized
NRBB52_0576 Hypothetical protein X No hit Uncharacterized
NRBB52_0577 Beta-glucosidase X PF00232 Uncharacterized
NRBB52_0578 Oligopeptide-binding protein (oppA) PF00496 Uncharacterized
NRBB52_0579 Oligopeptide transport system permease protein oppB PF00528 Uncharacterized
NRBB52_0580 Permease protein of ABC transporter system for peptides PF00528 Uncharacterized
NRBB52_0581 Oligopeptide transport ATP-binding protein oppD PF00005 Uncharacterized
NRBB52_0582 Oligopeptide transport ATP-binding protein oppF PF00005 Uncharacterized
NRBB52_0583 Beta-galactosidase PF00005 Uncharacterized
NRBB52_0584 Transcriptional regulator PF13377 Uncharacterized
Sucrose Bbr_0018 Hypothetical membrane spanning protein PF04854 Uncharacterized
Bbr_0019 Transcriptional regulator, LacI family PF13377 Uncharacterized
Bbr_0020 Beta-fructosidase or sucrose-6-phosphate hydrolase X PF00251 Uncharacterized
Bbr_0021 Solute-binding protein ABC transporter X PF13416 Uncharacterized
Tetracycline BB139W423_0392 Transposase PF00665 Uncharacterized
Continued
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Cluster Locus_tags Annotation
GTM 
positive PFAM Reference
BB139W423_0393 Ribosomal protection tetracycline resistance protein X PF00009 Uncharacterized
Erythromycin NRBB51_1106 Transposase PF10551 Uncharacterized
NRBB51_1107 Transposase PF00872 Uncharacterized
NRBB51_1108 Dimethyladenosine transferase (ErmX) X PF00398 Uncharacterized
NRBB51_1109 Transposase PF10551 Uncharacterized
NRBB51_1110 Transposase PF00872 Uncharacterized
NRBB51_1111 Dimethyladenosine transferase (ErmX) X PF00398 Uncharacterized
NRBB51_1112 Transposase PF10551 Uncharacterized
NRBB51_1113 Transposase No hit Uncharacterized
NRBB51_1114 Dimethyladenosine transferase (ErmX) X PF00398 Uncharacterized
NRBB51_1115 Transposase PF10551 Uncharacterized
NRBB51_1116 Transposase PF01610 Uncharacterized
Aminoglycosides CNCMI4321_0985 Aminoglycoside phosphotransferase (APH) X PF01636 Uncharacterized
CNCMI4321_0986 N-acetyltransferase (AAC) X PF00583 Uncharacterized
CNCMI4321_0987 Aminoglycoside adenylyltransferase (ANT) X PF04439 Uncharacterized
EPS biosynthesis Bbr_0430 Undecaprenyl-phosphate galactosephosphotransferase X PF02397 Fanning et al.55
Bbr_0431 Protein tyrosine phosphatase X PF01451 Fanning et al.55
Bbr_0432 Transposase PF01695 Fanning et al.55
Bbr_0433 Transposase PF00665 Fanning et al.55
Bbr_0434 Oligosaccharide repeat unit transporter (flippase) X PF01943 Fanning et al.55
Bbr_0444 Membrane spanning EPS biosynthesis protein (flippase) X PF01943 Fanning et al.55
Bbr_0435 Beta-1,6-N-acetylglucosaminyltransferase PF02485 Fanning et al.55
NRBB56_0458 UDP-galactopyranose mustase PF03275 Uncharacterized
NRBB50_0526 Hypothetical thiamine pyrophosphate enzyme TPP X PF02776 Uncharacterized
NRBB50_0514 Hypothetical membrane spanning protein (polymerase?) X No hit Uncharacterized
Bbr_0436 Hypothetical membrane spanning protein (polymerase) X PF14897 Fanning et al.55
Bbr_0450 Membrane spanning protein (polymerase) X PF14897 Fanning et al.55
Bbr_0437 Acetyltransferase PF00132 Fanning et al.55
Bbr_0446 Acetyltransferase (cell wall biosynthesis) PF00132 Fanning et al.55
Bbr_0451 Acyltransferase PF01757 Fanning et al.55
Bbr_0438 Glycosyltransferase X PF00535 Fanning et al.55
Bbr_0445 Glycosyltransferase X PF00535 Fanning et al.55
Bbr_0448 Glycosyltransferase X PF00535 Fanning et al.55
Bbr_0443 Glycosyltransferase X PF00534 Fanning et al.55
Bbr_0441 Capsular polysaccharide biosynthesis protein X PF00534 Fanning et al.55
Bbr_0442 Capsular polysaccharide biosynthesis protein X PF00534 Fanning et al.55
Bbr_0439 Capsular polysaccharide biosynthesis protein X PF05704 Fanning et al.55
Bbr_0440 Polysaccharide biosynthesis protein X PF14393 Fanning et al.55
Bbr_0447 Conserved hypothetical protein PF04230 Fanning et al.55
Bbr_0449 Hypothetical membrane spanning protein No hit Fanning et al.55
Bbr_0452 Hypothetical protein No hit Fanning et al.55
Bbr_0453 Transposase PF01695 Fanning et al.55
Bbr_0454 Conserved hypothetical protein No hit Fanning et al.55
Bbr_0455 Transposase PF01695 Fanning et al.55
Bbr_0456 Transposase PF00665 Fanning et al.55
Bbr_0457 Transposase PF00665 Fanning et al.55
Bbr_0458 Hypothetical protein No hit Fanning et al.55
Bbr_0459 Conserved hypothetical protein PF07693 Fanning et al.55
Bbr_0460 Hypothetical membrane spanning protein No hit Fanning et al.55
Bbr_0461 Hypothetical protein No hit Fanning et al.55
Bbr_0462 Transposase PF01695 Fanning et al.55
Bbr_0463 Transposase PF00665 Fanning et al.55
Bbr_0464 Hypothetical protein PF14280 Fanning et al.55
Bbr_0465 Hypothetical protein PF14253 Fanning et al.55
Bbr_0466 Hypothetical protein No hit Fanning et al.55
Bbr_0467 Conserved hypothetical protein with a helix-turn-helix motif PF01381 Fanning et al.55
Continued
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sucrose as well as palatinose and, though to a lesser extent, growth on turanose and fructose, thus supporting the 
notion that this cluster is involved in the utilization of a diverse range of fructose-containing substrates (Fig. 2B).
In order to verify the involvement of the genes encoding the predicted β-fructosidase (designated here as bfrA, 
corresponding to locus tag Bbr_0020) and solute binding protein (designated here as brfB, corresponding to locus 
tag Bbr_0021) in the utilization of fructose-containing moieties, they were targeted for insertional mutagenesis 
in B. breve UCC2003. Wild type B. breve UCC2003 and the isogenic strains carrying a mutation in either bfrA or 
bfrB (designated here as B. breve UCC2003-0020 and B. breve UCC2003-0021, respectively) were tested for their 
ability to grow on sucrose. As can be observed from the obtained growth profiles (Fig. 3B) both insertion mutant 
strains exhibited reduced growth on sucrose, thus confirming the GTM predictions. Notably, growth on sucrose 
was not fully eliminated, probably because sucrose may be metabolized by alternative routes in B. breve UCC2003 
(e.g. a sucrose phosphorylase Bbr_100, an ABC transporter Bbr_0026-27, an additional β-fructofuranosidase 
Bbr_1324 and a fructose phosphotransferase PTS system Bbr_1594)23,28,42. Of the 35 substrates for which dif-
ferential growth was observed among B. breve strains, some of these (e.g. starch and starch-like polysaccha-
rides, lacto-N-neotetraose, and galactose), did not return any useful positive matches when employing GTM. 
Apparently, utilization of certain carbohydrates may be influenced by factors other than the simple presence/
Cluster Locus_tags Annotation
GTM 
positive PFAM Reference
Bbr_0468 Hypothetical protein No hit Fanning et al.55
Bbr_0471 Hypothetical protein PF12686 Fanning et al.55
Bbr_0472 Conserved hypothetical membrane spanning protein PF13425 Fanning et al.55
Bbr_0473 Conserved hypothetical protein No hit Fanning et al.55
Bbr_0474 Chain length regulator PF13614 Fanning et al.55
Table 1. List of gene families (and surrounding regions with associated functions) returning positive hits in 
GTM analysis.
Figure 3. GTM analysis applied to carbohydrate utilization by B. breve. GTM in B. breve conducted for 337 
presence/absence clusters and 37 potential growth substrates. Substrates were excluded from the displayed 
analysis if they supported growth of all tested strains or if no growth was observed for any of the strains 
(Supplemental Table S3). Panel A: Heatmap showing gene clusters that match growth patterns on seven 
substrates (cellobiose, galactan, mannitol/sorbitol, melezitose, ribose, salicin and sucrose). Panel B: Insertional 
mutagenesis and assessment of the sucrose utilization in B. breve UCC2003. Diagrams showing growth curves 
of B. breve UCC2003 and B. breve UCC2003-0020/21 insertional mutants in sucrose.
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absence of genes (e.g. gene regulation, but also involvement of multiple distinct pathways or point mutations), 
and in such cases a different approach will be required to identify the genes involved.
GTM applied to antibiotic resistance. The use of GTM to discover carbohydrate utilization gene clus-
ters in B. breve encouraged us to apply this method to antibiotic resistance phenotypes. In order to generate our 
phenotypic dataset, the 20 B. breve strains were tested for their sensitivity to a range of antibiotics (Supplemental 
Table S4). Based on analysis tetracycline (Tet), erythromycin (Ery) and aminoglycoside (streptomycin; Str) resist-
ance phenotypes were detected for B. breve 139W4-23, B. breve NRBB51/DRBB26 and B. breve CNCM I-4321/
DRBB28, respectively (Fig. 4A).
In order to assess whether the presence/absence of antibiotic resistance genes is linked to a corresponding 
resistance phenotype, GTM analysis was employed using the same approach as described for carbohydrate utili-
zation. In the case of Tet resistance, a clear tetW homolog, conferring ribosomal protection from translation inhi-
bition by Tet43, was found in the genome of B. breve 139W4-23 (locus tag BB139W423_0393), thus representing a 
perfect match with the observed phenotype (Fig. 4B). In B. breve 139W4-23 the tetW homolog is surrounded by 
multiple transposases, suggesting acquisition by horizontal transfer.
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Figure 4. GTM analysis applied to antibiotic resistance in B. breve. Antibiotic resistance markers in the 20 
B. breve genomes with corresponding phenotypic assays. Panel A: Heatmap representing presence /absence 
of identified antibiotic resistance markers across 20 B. breve strains matching the observed phenotype. Panel 
B: Locus map representing the surrounding regions of the identified antibiotic resistance markers (e.g. 
tetracycline, erythromycin and aminoglycoside resistance) returning positive match in GTM.
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For erythromycin resistance, multiple copies of an ermX gene were found in the genome of B. breve 
NRBB51 (three copies) and B. breve DRBB26 (two copies), and were shown to be interleaved by predicted 
transposase-encoding genes (Fig. 4B). Erythromycin resistance in bifidobacteria has previously been described in 
B. thermophilum, where the ermX gene is flanked by Tn5432-like transposons44, similarly with what we observed 
in this strain. Employment of long-reads from Pacbio SMRT sequencing (average read length 14 Kb) accurately 
identified multiple repetitions of the Tn5432-ermX system within a 10 Kb chromosomal region, otherwise not 
easily detectable with the sole employment of short-read sequencing which generally results in a shorter and 
gapped consensus. The erythromycin resistance observed for B. breve NRBB51 represents a positive GTM match 
with the presence of the Tn5432-ermX system in this strain. Closer inspection of the ermX locus in B. breve 
DRBB26 revealed the presence of a structural variation in this genome resulting from the reshuffling of the two 
transposases preceding the ermX genes, which may have significantly lowered the erythromycin resistance of 
this strain (<0.5 μg/ml). Interestingly, the presumed acquisition of this locus through horizontal gene trans-
fer (HGT) is also corroborated by the finding that the ermX locus in B. breve NRBB51 is located on a putative 
integrative conjugative element (data not shown). To confirm that ermX of NRBB51 (corresponding to locus 
tag NRBB51_1114) confers erythromycin resistance this gene was cloned into pNZ44 resulting in plasmid 
pNZ44-Ery, of which introduction into the erythromycin-sensitive B. breve UCC2003 resulted in the expected 
antibiotic resistance phenotype (Table 2).
For aminoglycoside resistance, GTM analysis pointed to a genetic locus containing three predicted amino-
glycoside transferases in B. breve CNCM I-4321 (corresponding to locus tags CNCMI4321_0985-87) (Fig. 4B) 
and B. breve DRBB28 (locus tags DRBB28_1389-91). In both cases, these genes are present within a chromo-
somal region with a lower G + C content (40%) as compared to the average G + C content (59%), suggesting 
HGT acquisition. Based on analyses employing the comprehensive antibiotic resistance CARD/ARDB (https://
card.mcmaster.ca) and PFAM (http://pfam.xfam.org) databases, this locus appears to encode three enzymes each 
responsible for a particular modification (Table 1, Fig. 4A) that on its own or in combination may inactivate one 
or more aminoglycosides.
Based on the predicted functions, cloning of the genes within the CNCMI4321_0985-87 locus either 
together or individually was performed and their possible activity against a range of aminoglycosides was 
assessed. The result of the cloning experiments specifically assigned streptomycin resistance to the predicted 
nucleotidyl-transferase encoding gene (CNCMI4321_0987) (Table 2), thus resulting in the identification of several 
antibiotic selection markers, which in turn may be used to develop novel genetic tools specific for bifidobacteria.
GTM applied to EPS production. In order to extend our GTM analysis to a third phenotype, we investi-
gated whether the presence/absence of certain exopolysaccharide (EPS)-biosynthesis related genes would result 
in a corresponding EPS production phenotype and furthermore deduce a possible consensus for B. breve EPS 
“producers” and “non-producers”.
Gene content comparison of the EPS region, when applied to 20 fully sequenced representatives of B. breve, 
revealed that this locus, despite being always present at the same chromosomal position across the species, is one 
of the most variable genomic regions, with a very substantial difference in gene content and size across strains 
ranging between 5 and 58 Kb (Supplemental Fig. S2).
As previously described for certain bifidobacterial strains (among which are B. breve UCC2003, B. longum 
subsp. longum 35624TM and B. animalis subsp. lactis A1dOxR), bifidobacterial derivatives that do not produce 
EPS can be discriminated from their EPS-producing parental strains because the former strains sediment when 
cultivated in liquid growth media45–48. This phenotypic assay was carried out on the 20 B. breve strains and indi-
cated that in 60% of the cases (12 representatives) EPS production did occur, while for the remaining 40% of the 
strains (8 representatives) no EPS appeared to be produced as such strains exhibit a clear sedimentation pheno-
type in liquid medium (Fig. 5B).
By a first comparison of the phenotypic assay with the size of the EPS region across B. breve, no significant 
correlation between EPS production and the size of the locus was observed. However, our data delineated that 
B. breve EPS loci longer than 50 Kb are more likely to be complete and contain all necessary functions required for 
EPS biosynthesis, while loci < 30 Kb probably constitute incomplete and non-functional systems (Supplemental 
Fig. S2). In the case of EPS regions of a size between 30 and 50 Kb, either EPS “producers” or “non-producers” 
were observed, suggesting that EPS biosynthesis gene clusters of this size may still contain all genetic information 
Antibiotic
Highest level 
tested (μg/ml)
UCC2003 
pNZ44
UCC2003 pNZ44-
Str (0985-87)
UCC2003 
pNZ44-0985
UCC2003 
pNZ44-0986
UCC2003 
pNZ44-0987
UCC2003  
pNZ44-Ery (1114)
Aminoglycosides Amikacin 256 Res Res Res Res Res NA
Kanamycin 256 Res Res Res Res Res NA
Tobramycin 128 Res Res Res Res Res NA
Streptomycin 1024 Sen Res* Sen Sen Res* NA
Gentamicin 24 Sen Sen Sen Sen Sen NA
Netilmicin 48 Res Res Res Res Res NA
Erythromycin Erythromycin 256 Sen NA NA NA NA Res*
Table 2. Assessment of antibiotic resistance markers. *Confirmation of GTM Predictions for streptomycin 
and erythromycin. Res = resistant strain to the level tested; Sen = sensitive strain to the level tested; NA = not 
applicable.
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for EPS production. Furthermore, a complete deletion of this region (B. breve NRBB09) indeed corresponded to 
the expected EPS-negative phenotype.
In order to further investigate which combination of presence/absence of genes would result in a successful 
capsule biosynthesis, a comparative analysis of the genes present in this region was performed across strains and 
compared with the observed phenotype in a GTM approach. The analysis elucidated that a given B. breve strain 
can be classified as an EPS “producer” if it possesses the following characteristics: a) locus size > 30 Kb, b) at 
least three glycosyltransferase(GT)-encoding genes, c) an additional GT-encoding gene typically found at the 
beginning of the locus and representing the priming glycosyltransferase, d) a gene encoding a flippase, e) a gene 
encoding a tyrosine kinase or chain length determinant, f) an acetyltransferase often found in the vicinity of a 
polymerase-encoding gene or, alternatively, a thiamine pyrophosphate (TPP) binding protein always present in 
association with a membrane spanning protein which presumably represents the polymerase (Figs 5A,C). In sum-
mary, the GTM analysis allowed to explain the EPS production of 10 out of 12 strains (Fig. 5A and C). Notably, 
strains 215W4-47a and NRBB56 phenotypically behave as EPS “producers”, though our genetic analysis did not 
identify a candidate gene for a polymerase in the associated EPS locus. Other genetic functions, such as those 
encoding putative acetyltransferase, UDP-galactopyranose mutase and chain length-determining activities, did 
not appear to be able to discriminate “producers” from “non-producers” as they either occur in a limited number 
of strains or all strains (Fig. 5A). Therefore, our comparative and GTM analysis when applied to EPS production 
in B. breve defined gene functions which can be used for in silico discrimination between potential EPS “produc-
ers” and “non-producers”, thus facilitating the in silico screening of B. breve genomes for this phenotypic trait.
Conclusions
Comparative genome analysis represents a powerful bioinformatics tool to assess gene distribution across mem-
bers of a given species. If combined with pan-genomic extrapolations, gene comparisons may also allow iden-
tification of genes that are responsible for strain diversification. The presence of gene families that are variably 
present across members of a given species can be used as a starting point for phenotypic investigations using 
GTM. Our efforts to assess 20 B. breve representatives for a number of different phenotypes generated novel 
information about the implications of the genetic diversity observed for this species (e.g. carbohydrate utilization 
capabilities and EPS biosynthesis).
The main advantage of GTM as compared to classical approaches, generally based on single strain investi-
gation and not employing comparative genomic analysis, is that the first method is a much faster, yet accurate 
method to pin-point variably distributed genes, even within large genomic regions, being responsible for different 
phenotypic traits. Our findings indeed show that GTM can be used to identify genes involved in carbohydrate 
utilization in B. breve and by extension (bifido)bacteria in general.
Figure 5. GTM analysis applied to EPS production by B. breve. GTM applied to EPS production phenotype in 
B. breve. Panel A: Heatmap representing the EPS-associated genetic functions of which presence matched the 
observed EPS production phenotype (red) across the assessed B. breve strains. Five strains showing discrepant 
genotype/phenotype association are italicized. Panel B: EPS production phenotypic assay. Non-EPS-producers 
clearly show apparent reduction in OD as they ‘sediment’ to the bottom of the tube, while EPS producers do not 
exhibit such a sedimentation phenotype.
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Expansion of this analysis to a different phenotypes allowed the identification of novel antibiotic resistance 
markers which may be useful to develop novel cloning vectors specific for B. breve or bifidobacteria in gen-
eral. Moreover, the application of GTM to a more complex phenotype such as capsule biosynthesis constituted 
a challenge for the analysis, in particular because EPS production is the result of a combination of presence and 
co-occurrence of multiple genes. Furthermore, in this case the comparative genome analysis and GTM allowed 
us to identify genetic functions linked to the observed phenotype, thereby facilitating the distinction between EPS 
“producers” and “non-producers”.
Taken together, our study shows that comparative genome analysis can be integrated with phenotypic inves-
tigations in order to identify candidate genes responsible for various phenotypic traits, thereby generating new 
information on the unique genetic features of members of this bifidobacterial species.
Materials and Methods
In silico comparative analyses and pan-genome computation. We selected the prototype strain 
B. breve UCC200331 as a reference for our study, supplemented by 19 B. breve representatives (Supplemental 
Table S1) from a collection of B. breve human isolates, that had been sequenced in a previous study30. Comparative 
genome analyses and alignments for these 20 selected B. breve strains were carried out at protein level using 
“all-against-all”, bi-directional BLASTP alignments49 (cut-off: E-value < 0.0001, with at least 50% identity across 
at least 50% of either protein sequence). Identified ORFs were organized, based on these BLASTP outputs, in 
functionally related protein families employing the Markov Cluster Algorithm (MCL) implemented in the mcl-
blastline pipeline v12-067850. Comparative genome analyses then allowed the classification of the obtained gene 
families into either the core- or the dispensable-genome based on the presence of homologs in either all strains or 
in a subset of them, respectively. Pan-genome computation was performed using the online available PGAP v1.2 
pipeline, which uses the Heap’s law pan-genome model; genes were clustered using the GF (Gene Family) method 
implemented in the pipeline51.
Genotype/phenotype associations among B. breve strains. Carbohydrate-dependent growth profile 
analysis of B. breve strains was performed employing potential saccharide and saccharide-containing growth 
substrates (77 different growth substrates; Supplemental Table S3). For growth analysis, a 5% (w/v) stock solution 
of a given substrate (Supplemental Table S3) was prepared using distilled water. The obtained solution was filter 
sterilized using a 0.45 μm membrane filter and stored at 4 °C until required. To test the growth potential of each 
B. breve strain, modified de Man Rogosa and Sharpe (mMRS) medium was used, formulated based on the absence 
of any carbohydrate source (other than those to be tested). The medium was freshly prepared from first princi-
ples52 and supplemented with 0.5% (v/v) of an individual growth substrate solution and 0.05% (v/v) of L-cysteine 
HCl as essential nitrogen source for bifidobacterial growth. To this medium, 1% (v/v) of an overnight B. breve 
culture previously cultivated in 1% glucose or lactose, depending on the strain, was added. In some cases, in par-
ticular for poorly soluble carbohydrates (i.e. arabinoxylan, galactan, glycogen, starch, amylopectin, pullulan and 
maltodextrin), the substrate was directly added to mMRS at a final concentration of 0.5% prior to autoclaving at 
121 °C for 15 minutes. Medium without any supplemented carbohydrate was used as a negative control for each 
experiment, while medium with lactose was used as a positive control. Cultures were grown anaerobically at 37 °C 
and optical density measurements were recorded at OD600nm at regular intervals within 24 hours. Growth profiles 
were obtained using an automated microplate spectrophotometer (MultiScan FC Reader, Thermo Fisher). In 
the case of poorly soluble carbohydrates OD600nm measurements were taken manually using a UV-1280 spectro-
photometer (Shimadzu Corporation, Kyoto, Japan). Results were presented as a binary heatmap where growth/
no-growth patterns were deduced based on the following optical density cut-off values at 12 hours of incubation: 
(no growth = OD600 < 0.2; good growth = OD600 > 0.3; intermediate growth = OD600 > 0.2 and < 0.3), slightly 
adjusted from a previous publication39.
An in silico genotype/phenotype or GTM analysis was performed to associate presence/absence of specific 
gene families from the variome with a phenotype. Based on the fact that carbohydrate utilization capabilities are 
conferred by the presence of specific gene clusters, we organized presence/absence of gene families (retrieved 
by comparative genome analysis) and growth/no-growth phenotype, and the selection of candidates was per-
formed for each phenotype on an individual basis, as described previously22,53. In order to apply GTM analysis 
to carbon source utilization, identified gene families were filtered to exclude those that are present in all strains, 
as not contributing to strain diversification. Elements of the B. breve variome related to bacteriophage, certain 
mobile elements (e.g. integrated episomes and prophages) and phage-defence mechanisms (e.g. CRISPR/Cas and 
restriction-modification systems), which are not assumed to be associated with carbon source utilization, were 
also removed from the GTM analysis.
The gene families obtained in this manner were further clustered into unique combinations of occurrence 
across strains and a binary matrix was then deduced from the dataset (values 0 for absence and 1 for presence 
of a cluster). The thus generated “genotype” matrix contains 337 clusters as rows and 20 strains as columns. The 
same approach was adopted to cluster the obtained fermentation profiles resulting in a binary matrix constituting 
the “phenotype”. For this purpose a lower limit OD600nm of 0.3 was used as cut-off value to discriminate between 
substrates that did or did not support growth of a given strain (values 1 and 0, respectively). The resulting “phe-
notype” binary matrix contained 37 carbohydrates (for which differential growth was observed) as rows and 20 
strains as columns, the latter organized in the same order as in the genotype matrix.
Percentage association between the presence of a particular cluster and a growth phenotype was represented 
in a heatmap. The obtained positive matches (>95% of match between “genotype” and “phenotype”) and adjacent 
genomic regions were further inspected by BLAST analysis, and compared with information retrieved from the 
Cazy database (http://www.cazy.org), EC (Enzyme Classification) database (http://www.expasy.ch/enzyme) and 
PFAM (http://pfam.sanger.ac.uk) alignments.
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Insertional mutagenesis in B. breve UCC2003. Experimental validation of the GTM prediction in rela-
tion to sucrose utilization was performed through insertional mutagenesis in B. breve UCC2003. Internal frag-
ments of the predicted β-fructosidase (Bbr_0020) and the solute binding protein (Bbr_0021) genes (410 bp and 
374 bp, respectively) were amplified by PCR using B. breve UCC2003 chromosomal DNA as template and specific 
primers (Supplemental Table S5). The insertional mutants B. breve UCC2003-0020 and B. breve UCC2003-0021 
were generated according to a previously described method54. Site specific recombination and integration of 
the tetW gene in the correct chromosomal locations were confirmed by colony PCR using appropriate primers 
(Supplemental Table S5).
Genotype/phenotype association applied to antibiotic resistance. Antibiotic resistance or suscep-
tibility was determined by spread plating 100 µl of a particular B. breve strain on reinforced clostridial agar (RCA), 
on which antibiotic disks or strips (Supplemental Table S4) had been placed, followed by anaerobic incubation at 
37 °C for 24 h and then scoring growth/no growth around disks. To identify antibiotic resistance genes in B. breve, 
we applied GTM to compare presence/absence of gene families with antibiotic susceptibility results. Positive 
GTM hits were further assessed using the Comprehensive Antibiotic Resistance Database (CARD/ARDB) 
(https://card.mcmaster.ca). Resistance gene searches were supported by BLASTP49 alignments using more strin-
gent criteria than those used for the comparative analysis, in order to reduce the occurrence of false positives 
(cut-off: E-value < 0.0001, with at least 80% of identity across at least 70% of either protein sequence).
Plasmid construction and cloning of antibiotic resistance genes. To validate the predicted func-
tionality of genes in erythromycin resistance, chromosomal DNA from B. breve NRBB51 was used as a template 
for PCR amplification of the ermX gene (corresponding to locus tag NRBB51_1114) using Q5 DNA polymerase 
and primer pair 1114 F and 1114 R (Supplemental Table S5), in which PstI and HindIII sites had been incor-
porated so as to facilitate ligation to the similarly digested pNZ44. The ligation was introduced into electro-
competent L. lactis NZ9000 by electroporation and transformants were selected on GM17 agar plus 5 μg/ml 
chloramphenicol, resulting in pNZ44-Ery. Plasmid pNZ44-Ery was then introduced into electrocompetent B. 
breve UCC2003 by electroporation and the resulting recombinant strain named B. breve UCC2003-pNZ44-Ery 
was checked for erythromycin resistance (Table 2).
To validate the predicted involvement of genes in conferring streptomycin (Str) resistance, chromosomal DNA 
from B. breve CNCM I-4321 was used as template for PCR amplification of the suspected Str-resistance cassette 
(encompassing three genes, corresponding to locus tags CNCMI4321_0985-87) using Q5 DNA polymerase, and 
primer pair 0985-87 F and 0985-87 R (Supplemental Table S5), which included PstI and HindIII sites to facilitate 
ligation to similarly digested pNZ44. The individual three genes of the Str-resistance cassette were also assessed 
using specific primer pairs 0985 F and 0985 R, 0986 F and 0986 R, and 0987 F and 0987 R (Supplemental Table S5). 
Ligations were introduced into electrocompetent L. lactis NZ9000 by electroporation and transformants were 
selected on GM17 agar supplemented with 5 μg/ml chloramphenicol and checked for the correct insert by 
sequencing. This resulted in plasmid pNZ44-Str (carrying the entire resistance locus CNCMI4321_0985-87) 
and pNZ44-0985, pNZ44-0986, pNZ44-0987 (carrying individual genes, plasmid names correspond to locus 
tag numbers). The resulting four plasmids were then introduced into B. breve UCC2003 by electroporation, and 
the resulting recombinant strains, named B. breve UCC2003-pNZ44-Str, B. breve UCC2003-pNZ44-0985, B. 
breve UCC2003-pNZ44-0986, and B. breve UCC2003-pNZ44-0987 were then checked for resistance to a range 
of aminoglycosides, including streptomycin (Table 2). B. breve UCC2003-pNZ44 was used as a negative control 
for these experiments.
Genotype/phenotype association as applied to EPS production. Exopolysaccharide (EPS) produc-
tion was determined by first culturing 100 µl of a particular B. breve culture in mMRS media anaerobically at 37 °C 
for ~ 16 h. These cultures were then thoroughly resuspended to bring cells in full suspension. Incubation was 
then continued without agitation and cell sedimentation phenotype was assessed by hourly OD600nm measure-
ments for each of the B. breve strains over a 6-h time period. An observed drop in optical density (OD600nm value 
substantially decreasing within the first 3 hours) was associated with a sedimentation phenotype, which in turn 
was presumed to correspond to an EPS negative phenotype. In order to establish associations between suspected 
EPS production phenotype and the presence of an intact gene cluster responsible for EPS biosynthesis, all genes 
contained in the EPS cluster of B. breve22,55 were first extracted and their presence/absence from comparative 
analysis was compared with the obtained phenotypic data in a gene-trait matrix-based approach analogous to the 
one described above.
Data deposition. All the sequences used for our analysis have been retrieved from GenBank database 
with the following accession numbers: CP000303.1, CP021384, CP021389, CP021386, CP021387, CP021388, 
CP023193, CP021391, CP021392, CP021393, CP021394, CP021559, CP021390, CP021552, CP021553, 
CP021554, CP021555, CP021557, CP021556, CP021558.
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